K-ras Oncogene – Page 2

Biotech Roundup: Compugen, Nxera Milestone Payments; Insmed Seeks $650M Offering

1 year ago talkbio0Tagged AstraZeneca, Bio, BMS, Breyanzi, Burning Mouth Syndrome, Celcuity, Compugen, K-ras Oncogene, luteolin-7-O-diglucuronide 4'-O-glucuronosyltransferase activity, milestone payments, Nordisk, Novartis, Nxera, United States Food and Drug Administration

Compugen, Nxera, milestone payments, Insmed, $650M offering, biotech, pharmaceuticals, Celcuity, Weave Bio, AstraZeneca, Novo Nordisk Foundation, FDA, LDT rule, BMS, Breyanzi, KRAS drug, Novartis

BridgeBio Launches KRAS-Targeted Cancer Startup with $200 Million in Venture Capital Funding

1 year ago talkbio0Tagged BridgeBio, cellular targeting, K-ras Oncogene, Neoplasms, newco, Precision Medicine, startup, venture

BridgeBio, KRAS, cancer, startup, venture capital, funding, newco, oncology, precision medicine, targeted therapies.

BridgeBio Secures $200 Million from Venture Capitalists to Propel Oncology Spinout Beyond KRAS Class

1 year ago talkbio0Tagged Biotechnology, BridgeBio, Cancer Therapeutic Procedure, Class, Drug Development, Health care facility, Investments, K-ras Oncogene, KRAS, Neoplasms, venture

BridgeBio, venture capital, oncology, spinout, KRAS class, cancer treatment, biotechnology, drug development, investment, healthcare.